[Combined effects of interferon alpha-A/D with fluoropyrimidine derivatives in the subrenal capsule assay]

Gan To Kagaku Ryoho. 1988 Aug;15(8):2285-90.
[Article in Japanese]

Abstract

The combined effects of interferon alpha-A/D (IFN alpha-A/D) with 5-fluorouracil and fluoropyrimidine derivatives such as 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur), UFT, 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5'-deoxy-5-fluorouracil (5'-DFUR), were examined by 4-day subrenal capsule assay. Four human tumor xenografts serially transplanted in athymic mice, H-111, SH-10 established from gastric cancers, CH-4 and CH-5 from colon cancers, were used. In this experiment, the adequate dose of each agent was estimated as 50 mg/kg for 5-FU, 473 mg/kg for tegafur, 433 mg/kg for UFT, 50 mg/kg for HCFU, 185 mg/kg for 5'-DFUR and 1 x 10(5) IU for IFN alpha-A/D, respectively. When synergistic, additive and subadditive effects were defined as positive combined effects, all combinations produced positive combined effects against H-111 and CH-5, while negative ones were observed for all combinations against CH-4. The combinations of 5-FU, HCFU and 5'-DFUR with IFN alpha-A/D produced synergistic effects against SH-10. These results indicate that the combination therapy of 5-FU and fluoropyrimidine derivatives with IFN alpha-A/D would be useful.

Publication types

  • English Abstract

MeSH terms

  • Animals
  • Colonic Neoplasms / pathology
  • Drug Synergism
  • Fluorouracil / administration & dosage*
  • Fluorouracil / pharmacology
  • Interferon Type I / administration & dosage*
  • Interferon Type I / pharmacology
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Stomach Neoplasms / pathology
  • Subrenal Capsule Assay*
  • Tegafur / administration & dosage*
  • Tegafur / pharmacology

Substances

  • Interferon Type I
  • Tegafur
  • Fluorouracil